Fruquintinib combo for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs — fruquintinib plus paclitaxel liposome plus nidaplatin — as a first treatment for people with advanced esophageal squamous cell carcinoma that has spread. It aims to see if this combination can help control the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer (esophageal squamous cell carcinoma) has spread or cannot be removed by surgery, and you have already had one type of treatment for it.
- You have at least one tumor that can be seen on scans and measured.
- Your blood counts and organ function (kidneys, liver, blood clotting) are good enough based on standard lab tests.
- You agree to use effective birth control during and for 3 months after treatment (if you could become pregnant or get someone pregnant), and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for advanced or returning esophageal squamous cell carcinoma after platinum chemotherapy. It aims to find a better option for people whose cancer has not responded to or has come back after initial treatment.
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
This trial tests whether adding a new drug called QL1706 to standard chemotherapy (two common cancer drugs) works better for advanced esophageal cancer that can't be surgically removed. The goal is to see if this combination helps patients live longer and controls the cancer better than chemotherapy alone.
This trial tests a new combination of three drugs (fruquintinib, camrelizumab, and capecitabine) for people with colorectal cancer that has spread or cannot be removed and has stopped responding to a standard first chemotherapy. It is for those whose cancer progressed after a specific first treatment called FOLFOXIRI.
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.